Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

FibroGenesis Identifies Mechanism Responsible for Blocking COVID19-Like Lung Inflammation

This image opens in the lightbox

News provided by

FibroGenesis

01 Jul, 2020, 19:23 GMT

Share this article

Share toX

Share this article

Share toX

Regenerative Medicine Company Advances Development of Fibroblast-Based Product as an "Off the Shelf" Cell-Treatment for Coronavirus Acute Respiratory Distress Syndrome (ARDS)

HOUSTON, July 1, 2020 /PRNewswire/ -- FibroGenesis announced today identification of molecular mechanisms associated with the potent reduction of lung inflammation previously reported by the Company in an animal model of COVID-19 lung failure. 

The Company disclosed data demonstrating that administration of PneumoBlast™ resulted in dramatic alterations of immunological signaling molecules called "cytokines".  The studies showed that PneumoBlast™ reduced concentrations of the inflammatory cytokines interleukin-1 beta, interleukin-6, interleukin-8, interleukin-17, interleukin-18, and Tumor Necrosis Factor alpha, TNFa.  Supporting the inflammation-inhibiting properties of PneumoBlast™, Company scientists observed an increase in anti-inflammatory cytokines interleukin-4, interleukin-10, interleukin-13 and interleukin-35, as well as regeneration-associated cytokines FGF-2 and HGF-1.  The cytokines found to be manipulated by PneumoBlast™ are known to be associated with survival and recuperation from COVID-19. 

Interleukin-1 beta (IL-1β): Mortality from acute respiratory distress syndrome (ARDS), is associated with increased IL-1β.  Studies have shown that administration of Anakinra, a drug specifically designed to block IL-1β, reduces mortality in patients with a COVID-19 associated cytokine storm, one of the other causes of death.

Interleukin-6 (IL-6):  In a review of 1,426 COVID-19 patients in nine separated studies, interleukin-6 levels were more than three times higher in patients with complicated COVID-19 compared with those with a non-complicated disease.  Furthermore, it was shown that higher levels of interleukin-6 correlated with death.   Supporting a causative role of interleukin-6 in pathology of COVID-19, studies have shown that administration of blocking antibodies to interleukin-6 reduces pathology of this disease.

Interleukin-8 (IL-8): Patients with ARDS show that elevated levels of IL-8 are associated with higher mortality.  IL-8 is known to recruit and activate neutrophils in the lung. Under normal circumstances, neutrophils serve to fight infections.  In the case of COVID-19, excessive neutrophils in the lung are believed to be associated with lethality.

Interleukin-17 (IL-17): Most of diseases associated with the immune system (Autoimmune diseases) have upregulated levels of both IL-17 and the cells which produce it, the Th17 cells. Patients with COVID-19 have dysfunctional blood vessels which predispose to excessive coagulation, believed to be caused by IL-17.  Additionally, IL-17 stimulates neutrophil infiltration into lungs.

Previously reported by the Company:

In one set of experiments, control-untreated-mice possessed a lung wet weight to body weight ratio (LWW/BW) of 3.7 mg/g.  Mice treated with lipopolysaccharide; an agent that induces COVID-19-like lung inflammation caused an increase of the LWW/BW ratio of 12.5 mg/g.  Administration of bone marrow mesenchymal stem cells (BMSCs) to lipopolysaccharide-treated-mice only reduced the LWW/BW ratio to 9.9 mg/g.  In strong contrast, PneumoBlast™ administration significantly reduced the LWW/BW ratio to 5.2 mg/g in lipopolysaccharide-treated-mice (p < .001).  PneumoBlast™ showed a 37% improvement in outcome compared to BMSCs, which was statistically significant (p < .005). More importantly, after the introduction of PneumoBlast™ fibroblast cell therapy, average LWW/BW ratios returned to baseline control numbers of healthy lungs, which resulted in no statistical difference between recovered lungs and normal/healthy lungs using PneumoBlast™.

When the lung inflammation marker interleukin-6 was assessed, control mice possessed 532.3 pg/ml of the cytokine, whereas lipopolysaccharide administration caused an increase to 4400.1 pg/ml.  Treatment with BMSCs resulted in a slight 26% decrease of IL-6 in the lipopolysaccharide-treated-mice to 3317.7 pg/ml, whereas PneumoBlast™ significantly reduced IL-6 by 80% to 896.2 pg/ml, which was highly significant (p < .001).  The use of PneumoBlast™ resulted in a 54% improvement over BMSCs (p < .001).  The introduction of PneumoBlast™ cell therapy resulted in a reduction of inflammation back to normal/healthy lung levels in just 24 hours.

"Expanding our research continues to build a compelling scientific justification for use of fibroblasts in treatment of COVID-19 ARDS," said Tom Ichim, Ph.D., Chief Scientific Officer of FibroGenesis.  PneumoBlast™ appears to offer new hope to patients suffering from COVID-19 associated lung disease."

"We continue to be impressed with the potency of fibroblasts and their ability to effectively halt fluid accumulation in the lungs and repair the damage," said Pete O'Heeron, President and CEO of FibroGenesis. "Compared to stem cells, fibroblasts appear to be a more robust and potent cell source."

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company developing an innovative solution for chronic disease treatment using human dermal fibroblasts. Currently, FibroGenesis holds 220+ U.S. and international issued patents/patents pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure and Heart Failure. Funded entirely by angel investors, FibroGenesis represents the next generation of medical advancement in cell therapy.

Visit www.Fibro-Genesis.com.

Logo - https://mma.prnewswire.com/media/1121989/FibroGenesis_Logo.jpg

Related Links

https://www.fibro-genesis.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.